Multiple myeloma drug Elrexfio receives conditional approval
By Lee, Hye-Kyung | translator Kang, Shin-Kook
24.06.17 05:21:37
°¡³ª´Ù¶ó
0
CPAC ¡°company should submit therapeutic confirmatory clinical trial test results¡±
Elrexfio is an orphan drug indicated as monotherapy to treat adult patients with relapsed or refractory multiple myeloma who have received three or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
Being a subcutaneously delivered B-cell maturation antigen (BCMA)-CD3-directed bispecific antibody (BsAb) immunotherapy, it owns the advantage of being able to be administered immediately compared to CAR-T cell therapy.
After rece
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)